Abstract
5522 Background: GOG-0262 is an advanced stage ovarian cancer phase III trial comparing standard paclitaxel (q3 week)/carboplatin to dose-dense paclitaxel (weekly)/carboplatin with and without bevacizumab per physician choice. ACRIN 6695’s primary objective was to determine whether CT perfusion (CTP) parameters are prognostic of progression-free survival (PFS) at 6 months (PFS-6) in a cohort of GOG-262 patients. Methods: FIGO stage III or IV patients with suboptimal surgical cytoreduction or undergoing neoadjuvant therapy were recruited and underwent CTP studies before (T0) and at 3- (T1) and 4-weeks (T2) after chemotherapy initiation. Target lesion blood flow (BF) and blood volume were derived with CTP software (GE Healthcare). The association of BF changes from baseline to T2, dichotomized at zero (ΔBF±), and the response rate (best confirmed response by RECIST criteria) and PFS-6 rate were assessed with Fisher’s exact tests. Cox regression model was used to assess the association between ΔBF± and time-...
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
